Skip to main content
xMedica

NCT07046260ClinicalTrials.gov

Prospective Study to Assess a Diagnostic Aid for Cancer

Prospective Cohort Study With Case Enrichment to Assess a Diagnostic Aid for Cancer in Symptomatic Subjects (PROCARES)

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The primary objective of this study is to establish the performance of two blood-based diagnostic aid test for cancer detection in individuals presenting with symptoms, signs, or findings suggestive of cancer.

Observational1,650 participants sought39 sites1 country

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-07-01; recorded start 2025-07-11
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Harbinger Health)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 39 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,650 participants (target), run at 39 sites.

How this score is built
  • Enrolment32/40

    1,650 participants (target)

  • Site count19/25

    39 sites

  • Country count0/15

    Single country

  • Planned duration6/10

    Planned over about 16 months

  • Sponsor scale1/10

    Harbinger Health has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The primary objective of this study is to establish the performance of two blood-based diagnostic aid test for cancer detection in individuals presenting with symptoms, signs, or findings suggestive of cancer.

Subjects 45 years of age and older presenting with symptoms, signs, and/or findings suggestive of one or more cancers originating from protocol-specified sites will be enrolled. Subjects will complete a blood draw for analysis by the investigational diagnostic aid test. For subjects with suspected cancer at enrollment, clinical outcomes will be determined following completion of a standard-of-care diagnostic work-up as clinically indicated. Subjects with a confirmed cancer diagnosis at enrollment must be treatment-naïve and will have diagnosis details collected at the time of enrollment. The results of the investigational diagnostic aid test will not be provided to investigators, treating clinicians, or subjects. Personnel performing clinical evaluations, determining final diagnoses, or reviewing diagnostic imaging and pathology reports will remain blinded to the results of the investigational test. All testing and associated analyses will be conducted in a blinded fashion, and test results will not inform clinical decision-making.

Conditions

  • Cancer

Eligibility

Eligibility
SexAll
Ages45 YearsNo maximum
Healthy volunteersNo
Sampling methodNON_PROBABILITY_SAMPLE

Study population

This study will enroll individuals 45 years of age or older who present with symptoms, signs, and/or have findings leading to a clinical suspicion or a diagnosis of one or more cancers originating from the following sites: * Biliary Tract * Colon * Esophagogastric Junction (EGJ) * Esophagus * Gallbladder * Head and Neck * Liver * Lung * Lymphatic System * Ovary * Pancreas * Rectum * Stomach

Eligibility as written in the registry

Inclusion Criteria: 1. Subjects aged ≥45 years at the time of informed consent 2. Provided written or electronic informed consent, according to local guidelines, signed and dated by the Subject or by a legal guardian prior to the performance of any study- specific procedures, sampling, or analyses 3. Presentation with symptoms, signs, and/or findings that raise clinical suspicion of one or more of the protocol-specified sites AND 1. undergoing diagnostic work-up to determine if cancer is present, but do not yet have a confirmed cancer diagnosis. Subject must be willing to undergo a standard diagnostic work-up per local SoC to establish clinical truth regarding the presence or absence of cancer OR 2. have a confirmed diagnosis of cancer, determined within 90 days prior to signing the Informed Consent Form, based on standard diagnostic procedures (histopathology, imaging, etc.) following presentation with symptoms, signs, and/or findings that raised a clinical suspicion of one or more cancers originating from the protocol-specified sites. Must be treatment-naïve for the diagnosed cancer at the time of enrollment. Exclusion Criteria: 1. History of any prior invasive or hematological malignancy (Individuals with completely resected ductal carcinoma in-situ or completely resected non-melanoma skin cancer are permitted) 2. Subject is suffering from any febrile illness defined as a temperature \>101.5°F within 48 hours prior to blood draw 3. Subject is pregnant (Self-reported) 4. Subject is a recipient of an organ transplant, blood transfusion within 120 days, or prior non-autologous (allogeneic) bone marrow or stem cell transplant (Subject with a corneal transplant can be considered for study entry) 5. Inability or unwillingness to comply with study procedures or follow-up requirement 6. Previous or current participation in any study sponsored by, or employment with, Harbinger Health 7. Participation in a clinical research study sponsored by an external organization which may interfere with study procedures or outcomes 8. Subject has any condition that in the opinion of the Investigator should preclude participation in the study

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeObservational
PhaseNot stated in the registry record
AllocationNot stated in the registry record
Intervention modelNot stated in the registry record
Primary purposeNot stated in the registry record
MaskingNot stated in the registry record
Enrolment1,650 participants sought

Sponsor and collaborators

  • Harbinger Health Sponsor

Arms and interventions

  • Patients with clinical suspicion of cancer or patients recently diagnosed with Cancer

    Individuals 45 years of age or older who have signs, symptoms, and/or findings that their doctor suspects may be related to cancer, or who have recently been diagnosed with cancer and have not received treatment for this cancer.

Interventions

  • Other Blood sample collection

    The study will collect up to 40 mL of whole peripheral blood in Streck Cell-Free DNA BCT® tubes from each participant.

Outcome measures

  1. Primary outcome

    Performance of two diagnostic aid tests among individuals presenting with symptoms, signs and/or clinical findings suggestive of one or more cancers originating from the protocol-specified sites: a multi-cancer (MC) and gastrointestinal-focused (GI) test

    * Predictive value of the Harbinger multi-cancer (MC) test by each readout category. * Predictive value of the Harbinger GI test by each readout category.

    Time frame 18 months

  2. Secondary outcome

    Quantify test readout distribution, likelihood ratio, and marginal classification distribution of each Harbinger test

    * Establish for each Harbinger test the classification distributions for non-cancer individuals, and for cancer cases overall and by early-stage (I and II) and late-stage (III and IV) and further by cancer type. * Establish for each Harbinger test the likelihood ratio for each readout category, overall, by cancer stage and further by cancer type. * Establish for each Harbinger test the classification category frequency distribution.

    Time frame 18 months

  3. Secondary outcome

    Establish cancer incidence in this intended use population

    -Establish the cancer incidence, overall and by early-stage (I and II) and late-stage (III and IV) and further by cancer type.

    Time frame 18 months

Dates

Dates
Start dateJuly 11, 2025 (actual)
Primary completionJuly 1, 2026 (estimated)
CompletionNovember 1, 2026 (estimated)
First postedJuly 1, 2025 (actual)
Last updatedMarch 11, 2026
Results postedNot stated in the registry record
Status last verifiedMarch 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

35 sites are recruiting

United States

United States
FacilityCityState or regionStatus
Southwest GastroenterologyAlbuquerqueNew MexicoWithdrawn
Velocity Clinical ResearchAnnapolisMarylandRecruiting
Premier Family PhysiciansAustinTexasRecruiting
Westchester Putnam GastroCarmelNew YorkRecruiting
Rocky Mountain GastroenterologyCentennialColoradoRecruiting
Christie ClinicChampaignIllinoisRecruiting
Capital Digestive CareChevy ChaseMarylandWithdrawn
Zoyla Almeida, MD PACoconut CreekFloridaRecruiting
Southern California Research CenterCoronadoCaliforniaRecruiting
Cancer Center of Middle GeorgiaDublinGeorgiaRecruiting
Associated Gastroenterologists of Central New YorkFayettevilleNew YorkRecruiting
Northlake Gastroenterology AssociatesHammondLouisianaRecruiting
Texas DigestiveHarlingenTexasRecruiting
Susquehanna Research GroupHarrisburgPennsylvaniaRecruiting
Hope and Healing Cancer ServicesHinsdaleIllinoisRecruiting
Activian Clinical Research (Scarsdale)HoustonTexasRecruiting
Huntsville Research Institute, LLCHuntsvilleTexasRecruiting
Hutchinson ClinicHutchinsonKansasRecruiting
Azzi ENT and Facial Reconstructive SurgeryJupiterFloridaRecruiting
Activian Clinical ResearchKingwoodTexasRecruiting
GIA Clinical Trials, LLCKnoxvilleTennesseeRecruiting
Prophase, LLCMargateFloridaRecruiting
Millennium Medical ResearchMiamiFloridaRecruiting
Regis Clinical ResearchMiamiFloridaRecruiting
Oncology Hematology SpecialistsMountain LakesNew JerseyRecruiting
Memorial Sloan Kettering Cancer CenterNew YorkNew YorkRecruiting
Hightower ClinicalOklahoma CityOklahomaRecruiting
Gastroenterology of Greater OrlandoOrange CityFloridaRecruiting
Millennium Physician GroupPort CharlotteFloridaWithdrawn
Palomar HealthPowayCaliforniaRecruiting
South Coast Gynecologic OncologySan DiegoCaliforniaRecruiting
Stuart Oncology AssociatesStuartFloridaRecruiting
Avita Clinical ResearchTampaFloridaRecruiting
Iowa ClinicWest Des MoinesIowaRecruiting
Wilmington Health, PLLCWilmingtonNorth CarolinaRecruiting
Pulmonary & Sleep Specialists of Northeast Georgia, P.CWinderGeorgiaRecruiting
Respiratory SpecialistsWyomissingPennsylvaniaRecruiting
Cancer Care Associates of YorkYorkPennsylvaniaRecruiting
Huron GastroenterologyYpsilantiMichiganWithdrawn

Study documents

No documents are linked in this registry record.

Changes over time

No changes have been recorded since we first ingested this record.

A change is recorded each time the sponsor updates the registry record. Status, dates, enrolment and sites appear here as they move.